Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|April 1, 2017

BioPharm International

  • BioPharm International-04-01-2017
  • Volume 30
  • Issue 4

Nanoparticle Deagglomeration Technology

The Thinky PR-1 Nanoparticle Dispersion Machine from Intertronics is a desktop unit that can disperse carbon nanotubes (CNT), graphene, and other 2D nanomaterials within a closed container.

The Thinky PR-1 Nanoparticle Dispersion Machine from Intertronics is a desktop unit that can disperse carbon nanotubes (CNT), graphene, and other 2D nanomaterials within a closed container. The dispersion is consistent, highly reproducible, and is typically accomplished in a few minutes. The Thinky PR-1 uses mechanical rotation and multi-directional ultrasonics to achieve a rapid and even particle dispersion. The machine has a temperature limit control in the ultrasonic bath to counter the temperature rise of water and materials as a result of ultrasonic energy, avoiding changes in physical material properties. The system is compatible with quantities as small as a 5 mL capacity vial to a 200 mL capacity stainless steel container. The Thinky PR-1 can be used for applications in drug delivery, imaging, tissue engineering, and biosensors. 

Intertronics 
 


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.
The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron’s cemdisiran (Livsayis), an RNAi therapy Regeneron licensed from Alnylam Pharmaceuticals, as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.